Traitement chimiothérapique actuel du cancer de l'ovaire

[en] Epithelial ovarian cancer is frequently diagnosed at advanced-stage disease and chemotherapy is nearly always required. Optimally debulked patients may need adjuvant chemotherapy while, most of the time this chemotherapy will be given to those with advanced-stage disease. Also relapses will be treated differently whether they occur early or late in the course of the disease. This paper reviews medical treatment modalities according to stage based on published data. Maintenance and consolidation treatments are also discussed. Finally a brief insight into new therapeutic tools is also given.

Disciplines :

Hematology

Author, co-author :

Paulus, Astrid ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale

Gennigens, Christine ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Fillet, Georges ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale

Loly, Catherine ; Université de Liège - ULiège > Département des sciences cliniques

Sautois, Brieuc ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Language :

French

Title :

Traitement chimiothérapique actuel du cancer de l'ovaire

Alternative titles :

[en] Chemotherapy of Ovarian Cancer: State of the Art

Publication date :

September 2007

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

539-47

Peer reviewed :

Peer reviewed

Available on ORBi :

since 31 March 2009

Statistics

Number of views

388 (21 by ULiège)

Number of downloads

3003 (11 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Richardson GS, Scully RE, Nikrui N, Nelson JH Jr. - Common epithelial cancer of the ovary (1/2). N Engl J Med, 1985, 312, 415-424.
Trimbos JB, Parmar M, Vergote I, et al. - International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst, 2003, 95, 105-112.
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. - Lancet, 2002, 360, 505-515.
Calvert AH, Newell DR, Gumbrell LA, et al. - Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989, 7, 1748-1756.
McGuire WP, Hoskins WJ, Brady MF, et al. - Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med, 1996, 334, 1-6.
Ozols RF, Bundy BN, Greer BE, et al. - Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol, 2003, 21, 3194-3200.
du Bois A, Luck HJ, Meier W, et al. - A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst, 2003, 95, 1320-1329.
Piccart MJ, Bertelsen K, Stuart G, et al. - Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gvnecol Cancer, 2003, 13, 144-148.
du Bois A, Weber B, Rochon J, et al. - Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol, 2006, 24, 1127-1135.
Bookman MA. - GOGO182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian cancer (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol, 2006, 24, 256s.
Vergote I, Rustin GJ, Eisenhauer EA, et al. - Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst, 2000, 92, 1534-1535.
Markman M, Federico M, Liu PY, Hannigan E, Alberts D. - Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol, 2006, 103, 195-198.
Markman M, Liu PY, Rothenberg ML, et al. - Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol, 2006, 24, 1454-1458.
Gadducci A, Zola P, Landoni F, et al. - Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol, 1995, 58, 42-47.
van der Burg ME, van Lent M, Buyse M, et al. - The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med, 1995, 332, 629-634.
Rose PG, Nerenstone S, Brady MF, et al. - Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med, 2004, 351, 2489-2497.
Hakes TB, Chalas E, Hoskins WJ, et al. - Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol, 1992, 45, 284-289.
Bertelsen K, Jakobsen A, Stroyer J, et al. - A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol, 1993, 49, 30-36.
Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. - A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol, 1997, 8, 327-333.
Pfisterer J, Weber B, Reuss A, et al. - Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst, 2006, 98, 1036-1045.
De Placido S, Scambia G, Di Vagno G, et al. - Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol, 2004, 22, 2635-2642.
Bolis G, Danese S, Tateo S, et al. - Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer, 2006, 16, 74-78.
Markman M, Liu PY, Wilczynski S, et al. - Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol, 2003, 21, 2460-2465.
Conte PF, Gadducci A, Cianci C. - Second-line treatment and consolidation therapies in advanced ovarian cancer. Int J Gynecol Cancer, 2001, 11, 52-56.
Pecorelli S, Odicino F, Favalli G. - Consolidation therapies revisited: weekly paclitaxel. Int J Gynecol Cancer, 2003, 13, 208-211.
Hall GD, Brown JM, Coleman RE, et al. - Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer, 2004, 91, 621-626.
Bruzzone M, Rubagotti A, Gadducci A, et al. - Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. Gynecol Oncol, 1997, 65, 499-505.
Berek JS, Taylor PT, Gordon A, et al. - Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol, 2004, 22, 3507-3516.
Thomas GM. - Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer? Gynecol Oncol, 1993, 51, 97-103.
Sorbe B. - Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy. Int J Gynecol Cancer, 2003, 13, 192-195.
Sorbe B. - Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer, 2003, 13, 278-286.
Kairemo KJ. - Radioimmunotherapy of solid cancers: A review. Acta Oncol, 1996, 35, 343-355.
Verheijen RH, Massuger LF, Benigno BB, et al. - Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol, 2006, 24, 571-578.
Vergote IB, Winderen M, De Vos LN, Trope CG. - Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second-look laparotomy. Cancer, 1993, 71, 2250-2260.
Varia MA, Stehman FB, Bundy BN, et al. - Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol, 2003, 21, 2849-2855.
Hofstra LS, de Vries EG, Mulder NH, Willemse PH. - Intraperitoneal chemotherapy in ovarian cancer. Cancer Treat Rev, 2000, 26, 133-143.
Markman M. - Intraperitoneal therapy of ovarian cancer. Semin Oncol, 1998, 25, 356-360.
de Gramont A, Demuynck B, Louvet C et al. - Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy. Am J Clin Oncol, 1992, 15, 7-11.
Tarraza HM Jr, Boyce CR, Smith WG, Jones MA. - Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy. Gynecol Oncol, 1993, 50, 287-290.
Dufour P, Bergerat JP, Barats JC, et al. - Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer, 1994, 73, 1865-1869.
Barakat RR, Almadrones L, Venkatraman ES, et al. - A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol, 1998, 69, 17-22.
Tournigand C, Louvet C, Molitor JL, et al. - Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission. Gynecol Oncol, 2003, 91, 341-345.
Topuz E, Eralp Y, Saglam S, et al. - Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer. Gynecol Oncol, 2004, 92, 147-151.
Sabbatini P, Aghajanian C, Leitao M, et al. - Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. Clin Cancer Res, 2004, 10, 2962-2967.
Piccart MJ, Floquet A, Scarfone G, et al. - Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer, 2003, 13, 196-203.
Legros M, Dauplat J, Fleury J, et al. - High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol, 1997, 15, 1302-1308.
Ledermann JA, Herd R, Maraninchi D, et al. - High-dose chemotherapy for ovarian carcinoma: longterm results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol, 2001, 12, 693-699.
Stiff PJ, Bayer R, Kerger C, et al. - High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol, 1997, 15, 1309-1317.
Shinozuka T, Miyamoto T, Muramatsu T, et al. - High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients. Cancer, 1999, 85, 1555-1564.
Cure H, Battista C, Guastalla JP, et al. - Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year followup of a GINECO/FNCLCC/SFGM-TC study. J Clin Oncol, 2004, 22, 5006.
Gordon AN, Fleagle JT, Guthrie D, et al. - Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol, 2001, 19, 3312-3322.
Parmar MK, Ledermann JA, Colombo N, et al. - Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 2003, 361, 2099-2106.
Pfisterer J, Plante M, Vergote I, et al. - Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG. and the EORTC GCG. J Clin Oncol, 2006, 24, 4699-4707.
Ferrero JM, Weber B, Geay JF, et al. - Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse : a GINECO phase II trial. Ann Oncol, 2006.
Markman M, Markman J, Webster K, et al. - Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol, 2004, 22, 3120-3125.
Baekelandt M, Lehne G, Trope CG, et al. - Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol, 2001, 19, 2983-2993.
Fracasso PM, Brady MF, Moore DH, et al. - Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol, 2001, 19, 2975-2982.
Kavanagh JJ, Gershenson DM, Choi H, et al. - Multiinstitutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer, 2005, 15, 593-600.
Bookman MA, Darcy KM, Clarke-Pearson D, et al. - Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2 : a phase II trial of the Gynecologic Oncology Group. J Clin Oncol, 2003, 21, 283-290.
Druker BJ. - Imatinib as a paradigm of targeted therapies. Adv Cancer Res, 2004, 91, 1-30.
Schmandt RE, Broaddus R, Lu KH, et al. - Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer, 2003, 98, 758-764.
Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. - Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol, 2006, 102, 140-144.
Barvaux VA, Lorigan P, Ranson M, et al. - Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by 06-alkylguanine-DNA alkyltransferase. Mol Cancer Ther, 2004, 3, 1215-1220.
Yuen AR, Halsey J, Fisher GA, et al. - Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res, 1999, 5, 3357-3363.
Mullen P, McPhillips F, MacLeod K, et al. - Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer. Clin Cancer Res, 2004, 10, 2100-2108.
Wilhelm SM, Carter C, Tang L, et al. - BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64, 7099-7109.
Dupont J, Aghajanian C, Sabbatini P, Spriggs DR. - New agents for the treatment of ovarian cancer: the next generation. Int J Gynecol Cancer, 2005, 15, 252-257.
Bazzaro M, Lee MK, Zoso A, et al. - Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res, 2006, 66, 3754-3763.
Sessa C, De Braud F, Perotti A, et al. - Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol, 2005, 23, 1867-1874.
Smith I. - Phase II studies of pemetrexed in metastatic breast and gynecologic cancers. Oncology (Williston Park), 2004, 18, 63-65.
Singer JW, Shaffer S, Baker B, et al. - Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs, 2005, 16, 243-254.
Larkin JM, Kaye SB. - Epothilones in the treatment of cancer. Expert Opin Investig Drugs, 2006, 15, 691-702.
Dark GG, Calvert AH, Grimshaw R, et al. - Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol, 2005, 23, 1859-1866.